Analysts See $-0.30 EPS for Cellect Biotechnology Ltd. (APOP) on June, 4

May 17, 2018 - By Megan Stone

On June, 4 Cellect Biotechnology Ltd. (NASDAQ:APOP)’s earnings report is anticipated by WallStreet, according to Zacks. Analysts have anticipation on stock’s earnings per share of $-0.30. That’s down 650.00 % from last year’s $-0.04 earnings per share. Wall Street predicts 87.50 % negative EPS growth as of June, 4. APOP reached $7.13 during the last trading session after $0.02 change.Currently Cellect Biotechnology Ltd. is downtrending after 42.02% change in last May 17, 2017. APOP has 17,074 shares volume. APOP underperformed the S&P 500 by 53.57%.

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel.The firm is valued at $46.41 million. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.Last it reported negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: